Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours

Por Baro, M, de Llobet, L I, Figueras, A, Skvortsova, I, Mesia, R, Balart, J
Publicado em 2014

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma

Por Oliva, M, Spreafico, A, Taberna, M, Alemany, L, Coburn, B, Mesia, R, Siu, L L
Publicado no Ann Oncol (2019)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: re...

Por Vermorken, J. B., Psyrri, A., Mesía, R., Peyrade, F., Beier, F., de Blas, B., Celik, I., Licitra, L.
Publicado em 2014

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

Por Vermorken, J B, Guigay, J, Mesia, R, Trigo, J M, Keilholz, U, Kerber, A, Bethe, U, Picard, M, Brummendorf, T H
Publicado em 2011

SEOM clinical guideline in nasopharynx cancer (2017)

Por Pastor, M., Lopez Pousa, A., del Barco, E., Perez Segura, P., Astorga, B. Gonzalez, Castelo, B., Bonfill, T., Martinez Trufero, J., Grau, J. Jose, Mesia, R.
Publicado no Clin Transl Oncol (2017)

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metasta...

Por Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., Störkel, S., Senger, S., Stroh, C., Vermorken, J. B.
Publicado em 2011

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Por Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Publicado em 2010

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/I...

Por Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Publicado em 2014

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locor...

Por van Herpen, C M L, Mauer, M E, Mesia, R, Degardin, M, Jelic, S, Coens, C, Betka, J, Bernier, J, Remenar, E, Stewart, J S, Preiss, J H, van den Weyngaert, D, Bottomley, A, Vermorken, J B
Publicado em 2010

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe

Por Mena, M., Frias-Gomez, J., Taberna, M., Quirós, B., Marquez, S., Clavero, O., Baena, A., Lloveras, B., Alejo, M., León, X., García, J., Mesía, R., Bermejo, O., Bonfill, T., Aguila, A., Guix, M., Hijano, R., Pavón, M. A., Torres, M., Tous, S., Clèries, R., Alemany, L.
Publicado no Sci Rep (2020)

318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Por Pinato, D.J., Zambelli, A., Bertuzzi, A., Marrari, A., Saoudi-Gonzalez, N., Mirallas, O., Galazi, M., Generali, D., Grisanti, S., Tondini, C., Prat, A., Tabernero, J., Mesia, R., Salazar, R., Sureda, A., Franchi, M., Chiudinelli, L., Illescas, D.G., Libertini, M., Gennari, A.
Publicado no Ann Oncol (2020)